ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (Part 1)

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL).

Balancing treatment efficacy versus toxicity is important and there is reference to the CLL10 study. Anti-CD1 monoclonal antibody therapy after completing chemotherapy, the 17p deletion, allogeneic transplants and a ‘chemo-free’ approach are also considered.